Last updated: 11/07/2018 07:08:29
Meta-analysis - eltrombopag
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Trial overview
Official title: Systematic review of the clinical and cost effectiveness of treatments for idiopathic (immune) thrombocytopenic purpura (ITP): direct meta analysis
Trial description: The purpose of the meta-analysis was to explore the efficacy of eltrombopag versus placebo (standard of care)
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
>=50 Gi/L platelet count to <400 Gi/L
Timeframe: 43 days
Secondary outcomes:
Not applicable
Interventions:
Drug: Eltrombopag
Drug: Placebo
Enrollment:
1
Observational study model:
Other
Primary completion date:
Not applicable
Time perspective:
Retrospective
Clinical publications:
Boyers D, Jia X, Jenkinson D, Mowatt G. Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura - A NICE Single Technology Appraisal. [Pharmacoeconomics]. 2012;30(6):483-495.
Medical condition
Thrombocytopaenia
Product
eltrombopag
Collaborators
Not applicable
Study date(s)
August 2009 to November 2009
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- Adults with ITP
- Received a pre-specified treatment
- Subjects with ITP due to other causes
Inclusion and exclusion criteria
Inclusion criteria:
- Adults with ITP
- Received a pre-specified treatment
- Prospective clinical studies with at least 10 patients
Exclusion criteria:
- Subjects with ITP due to other causes
Trial location(s)
No location data available.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Finalized
Actual primary completion date
Not applicable
Actual study completion date
2009-30-11
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website